Figure 6.

GPCR and EGFR potentiation of TRPV4 channels is PKC dependent. (A) Trypsin (25 U·mL⁻¹) or 2fLIGRLO-NH₂ (25 μM) dependent PAR2 activation and potentiation of TRPV4 channel-mediated-contraction (GSK101, 25 nM) in the mouse aorta is inhibited by PKC inhibitors Go6983 (0.3 μM) (B) EGF (50 ng·mL⁻¹) potentiation of TRPV4-dependent contraction (GSK101, 25 nM) in the mouse aorta is inhibited by PKC inhibitors Go6983 (0.3 μM) or GFX (0.3 μM). Data are expressed as the mean ± SEM. n = 3. *P < 0.05, significantly different from control group.